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objectives: To assess the effect of combination ticagrelor 180 mg and clopidogrel 600 mg (TC) on platelet reactivity compared to ticagrelor (T) 
alone in patients undergoing primary PCI.
Background: Rapid platelet inhibition is needed to prevent stent thrombosis in patients undergoing primary PCI. In the PLATO study, increasing 
doses of pre-randomization clopidogrel was associated with a trend towards clinical benefit in STEMI patients assigned to ticagrelor. 
methods: We measured platelet reactivity at multiple time points within 48 hours of loading with either T or TC in patients referred for primary PCI 
(PPCI) using the VerifyNow P2Y12 assay.
results: In total, 376 time points were assayed in STEMI patients (25 TC and 22 T) referred for PPCI. Mean baseline PRUs were similar between the 
groups (Figure, p=NS). By 2 hours, curves between the groups began separating with significantly lower PRUs observed in the TC arm at all remaining 
time points. Similarly, when analyzed as a categorical variable (PRU <208), combination therapy resulted in significantly more pts achieving 
therapeutic platelet inhibition at 1, 2, 4 and 6 hours.
conclusions: In patients referred for PPCI, loading with TC or T alone provided rapid and efficacious platelet inhibition; however, the combination 
of TC resulted in more rapid and more profound inhibition of platelet activity than T alone. Further studies are needed to determine if this 
pharmacodynamic interaction reduces clinical events. 
